Oral News and Research

RSS

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society.

28 Oct 2014

ETEC vaccine candidate provides significant protection against bacterial diarrhea

New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease.

28 Oct 2014

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.

27 Oct 2014

Bortezomib drug effective against chronic GVHD

Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease (GVHD), a common and debilitating side effect from allogeneic hematopoietic stem cell transplants.

27 Oct 2014

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma Corp. today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited, the originator of tosedostat, and Chroma Therapeutics Ltd., through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America.

27 Oct 2014

Population Council to present research on novel approaches to HIV prevention at HIV R4P 2014

The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.

27 Oct 2014

Enhanced dental care reduces respiratory tract infection risk in ICU patients

New research shows vulnerable patients in the Intensive Care Unit (ICU) who received enhanced oral care from a dentist were at significantly less risk for developing a lower respiratory tract infection (LRTI), like ventilator-associated pneumonia, during their stay.

25 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Henry Schein invests in Iwase Dental Supply

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it has invested in Iwase Dental Supply, Inc., a leading full-service provider of dental consumables, implants and equipment in Japan.

20 Oct 2014

New oral biologic medication successfully treats precancerous intestinal inflammation

An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of Medicine and Biomedical Sciences.

16 Oct 2014

Rose Medical Center experts perform LARIAT procedure for patients with atrial fibrillation

Rose Medical Center is now performing a groundbreaking procedure for patients with atrial fibrillation (AFib) that may reduce their risk for stroke when they cannot take blood thinners due to special circumstances.

16 Oct 2014

Actavis seeks FDA approval to market generic version of Quillivant XR

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR®, which is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

16 Oct 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Western Dental signs research collaboration agreement with UCSF

Western Dental, one of the nation's leaders in accessible, affordable oral health care, announced a first-of-its-kind research collaboration agreement with the University of California, San Francisco, a leading center of health sciences research, patient care, and education.

14 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

Opponents attempt to outlaw abortion state-by-state

The numbers have changed little over the decades: A majority of Americans support abortion. But across the country, the antiabortion movement has recorded major success in the last four years, part of a well-funded national strategy to legislate abortion out of existence state by state. Legislatures, many stocked with new Republican majorities, have passed laws that, if upheld, would drastically reduce access to abortion for millions of women (Semuels and La Ganga, 10/12).

14 Oct 2014

Tackling poor oral health among athletes

Poor oral health affecting athletes' general health and performance shows 'no signs of improvement' and must be remedied, say a group of UCL-led health experts and sporting bodies. In a consensus statement published in the British Journal of Sports Medicine, the authors call for action to tackle poor oral health among athletes.

14 Oct 2014

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.

14 Oct 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

Study shows potential of treating recurrent CDI with frozen fecal matter

A preliminary study has shown the potential of treating recurrent Clostridium difficile infection (a bacterium that is one of the most common causes of infection of the colon) with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent, according to a study published in JAMA.

13 Oct 2014

Oral News and Research

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

ETEC vaccine candidate provides significant protection against bacterial diarrhea

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

Bortezomib drug effective against chronic GVHD

CTI BioPharma acquires worldwide rights to tosedostat

Population Council to present research on novel approaches to HIV prevention at HIV R4P 2014

Enhanced dental care reduces respiratory tract infection risk in ICU patients

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Henry Schein invests in Iwase Dental Supply

New oral biologic medication successfully treats precancerous intestinal inflammation

Rose Medical Center experts perform LARIAT procedure for patients with atrial fibrillation

Actavis seeks FDA approval to market generic version of Quillivant XR

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Western Dental signs research collaboration agreement with UCSF

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Opponents attempt to outlaw abortion state-by-state

Tackling poor oral health among athletes

FDA approves new hepatitis C drug, Harvoni

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Study shows potential of treating recurrent CDI with frozen fecal matter

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News